Cargando…
Evaluating the benefits and adverse effects of an enthracycline-taxane-capecitabine combined regimen in patients with early breast cancer
Capecitabine in addition to anthracycline-taxane based regimens for patients with early breast cancer (EBC) has been reported in previous clinical trials, but the reported efficacy of this regimen remained inconsistent. In order to clarify the survival benefit of this regimen, a meta-analysis was pe...
Autores principales: | Zhang, Jiantang, Fu, Fangmeng, Lin, Yuxiang, Chen, Yazhen, Lu, Minjun, Chen, Minyan, Yang, Peidong, Huang, Meng, Wang, Chuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655315/ https://www.ncbi.nlm.nih.gov/pubmed/29113420 http://dx.doi.org/10.18632/oncotarget.20386 |
Ejemplares similares
-
The precision relationships between eight GWAS-identified genetic variants and breast cancer in a Chinese population
por: Chen, Yazhen, et al.
Publicado: (2016) -
Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer
por: Qiu, Lin, et al.
Publicado: (2016) -
Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens
por: Hansen, Ryan N, et al.
Publicado: (2014) -
Genetic variants in long noncoding RNA H19 contribute to the risk of breast cancer in a southeast China Han population
por: Lin, Yuxiang, et al.
Publicado: (2017) -
The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer
por: Lian, Weibin, et al.
Publicado: (2017)